Global Animal Biotechnology Market - 2022-2029
Animal Biotechnology Market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of YY % during the forecast period (2022-2029).
Animal biotechnology refers to using engineering, science, and technology to modify and improve living organisms such as animals. Animal biotechnology can also be further explained as part of biotechnology, where molecular biotechnology techniques are used to genetically manipulate or modify the genome of various animals to improve their suitability for various applications such as pharmaceutical, industrial or agricultural applications. In the same case, animal biotechnology uses multiple methods to diagnose the various diseases in animals, allow the treatment of these diseases through multiple therapeutic options and the development of veterinary drugs, and the preventive care of animals through veterinary vaccines. The vaccination process is a highly effective and crucial tool for preventing animal diseases and promoting animal health and welfare, safe food production and public health.
Recent advances in genetic engineering are expected to drive market growth.
Recent developments in genetic engineering have widened the area of biotechnology research and application in farm animals. Animals raised for food, such as cattle and poultry, provide high-quality protein, essential amino acids, minerals, fats, easily absorbed vitamins, trace amounts of carbohydrates, and other bioactive substances in their meat and milk. In the livestock industry, biotechnology is being used to accelerate breed development for greater animal welfare and health, increased reproduction, and improved nutritional quality and safety of products obtained from animals. Through a range of biotechnological techniques, such as artificial insemination, in-vitro fertilization, and somatic cell nuclear transfer, animal breeding stock is thus improved. For instance, using DNA markers to describe an animal's genetic make-up and predict its performance is useful in animal biotechnology. Marker-assisted selection is a technique for indirectly selecting a genetic determinant of an interesting feature. Many traits are governed by multiple genetic loci, each of which is referred to as a quantitative trait locus and contributes to the trait's variation. The producer may be given the option of transferring or discarding the embryo if significant quantitative characteristic loci are found in the embryo. Only genetic markers strongly related to the genes or objective attributes can ensure successful breeding in practice.
Additionally, recombinant DNA technology is another method that allows the creation of unique genetic fusions advantageous to animals by inserting a recombined DNA molecule known as rDNA into a host organism. DNA vaccines can elicit potent, long-lasting cellular immune responses because it enables the production of numerous copies of genes and the insertion of foreign genes into other species to impart new traits like antibiotic resistance and the production of animal vaccines. Thus, from the above statements, the market is expected to drive in the forecast period.
The high cost of animal biotechnology products, ethical concerns related to animal biotechnology products and lack of skilled professionals to perform diagnostic tests are some factors the market is expected to get hampered in the forecast period.
The animal biotechnology market provides in-depth analysis of the market based on various industry factors such as porter five forces, supply chain, pricing analysis, regulatory approvals etc.
COVID-19 Impact Analysis
The COVID-19 pandemic has moderately impacted the market. The coronavirus pandemic has brought biotechnology research's potential benefits and pitfalls into focus. Although such research can be used to develop medical countermeasures to combat disease and to develop healthier crops and livestock, it can also be used to create biological weapons. Researchers from all across the world are aggressively battling the pandemic. They've utilized several technologies to develop affordable diagnostics, repurpose current antivirals, find novel medicines, and manufacture certain and efficient vaccinations.
Additionally, genetically modified organisms that can be purposefully released into the environment for things like mosquito control can be made via biotechnology. For instance, developments in genome engineering technologies, like clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (Cas9), have made it possible to create gene drives. This method enables desired genetic alterations to spread quickly throughout a population over several generations. This technique can cure vector-borne human diseases such as malaria and dengue fever by either making mosquitoes resistant to the parasites that cause these diseases or completely wiping out disease-carrying mosquito populations. In contrast, medium- and small-sized enterprises had challenges due to the pandemic's restrictions on veterinary clinic visits. Therefore, the pandemic is interrupting the supply chain. Thus, the COVID-19 pandemic has affected the market. However, the situation is expected to improve gradually in the forecast period.
Vaccinations segment is expected to hold the largest market share in animal biotechnology market.
The vaccinations segment accounted for the largest market share in 2021. The segment is benefited from the rising incidence of animal diseases, which naturally spread from animals to humans through consumption of contaminated food and water or direct contact with plagued individuals. Animal illness burden can be decreased through vaccination, which is also a key component of disease prevention and control. Moreover, new vaccine manufacturing techniques have emerged due to advances in technology, medicine, and basic scientific fields like immunology, molecular biology, microbiology, and biochemistry. The application of newer vaccination theories has been aided by genetic engineering, proteomics, and other cutting-edge technologies, leading to the discovery of new ruminant vaccines and the improvement of current ones. The next generation of vaccinations, which are being examined as potential alternatives to traditional immunizations, include subunit, recombinant, DNA, and vector.
Additionally, there are increasing vaccine launches for animals. For instance, Boehringer Ingelheim India introduced VAXXITEK HVT+IBD, a vaccine for poultry, in May 2021. All varieties of producing hens, including broiler, layer, and breeder chickens, are guaranteed lifelong protection by a novel recombinant vaccine called VAXXITEK HVT+IBD. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period.
North America region holds the largest market share in the global animal biotechnology market
In 2021, North American animal biotechnology accounted for the highest revenue share in the global market. The increasing prevalence of zoonotic diseases, advances in genetic engineering in animals, and increasing initiatives and campaigns to promote animal health in the region are driving the market in the forecast period. For instance, according to Dr. Mark Walton, Chief Technology Officer at AquaBounty Technologies, AquAdvantage Salmon (AAS) presents several opportunities for addressing the impending fish shortage and developing a variety of nutrient-rich foods. According to Dr. Walton, AAS has faster development and improved feed efficiency, so it requires less time in water and feeds to get a kilo of proteins. The scientist added that AAS genetics is crucial to the system's profitability and that the AquAdvantage system is witnessing a significant rise in investment. The scientist asserted that the spread of salmon farming in recirculating aquaculture systems on land in the US and internationally would be significantly aided by AquAdvantage.
Furthermore, the Canadian Agricultural Partnership will start contributing up to $4 million in January 2021 to give farmers better access to veterinary services when and when they need them. To enable a collaborative and coordinated approach to transform technologies in the field of veterinary vaccines, biologicals, and diagnostics, TRPVB is a cooperation initiative between the Department of Biotechnology, India, and TANUVAS-Chennai. Therefore, it has increased the demand for animal biotechnology in the region. Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.
Major key players in the animal biotechnology market are Boehringer Ingelheim GmbH, Merck & Co.,Inc., Virbac, Elanco, Zoetis, Biogénesis Bagó, Idexx Laboratories, Heska Corporation, Indian Immunologicals Ltd. and HESTER BIOSCIENCES LIMITED.
Boehringer Ingelheim GmbH:
Boehringer Ingelheim is one of Germany's leading contract manufacturers of biopharmaceuticals based on cell cultures and microorganisms. The company is divided into three business areas: human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing. Moreover, in the animal health sector, Boehringer Ingelheim is one of the world's leading suppliers of vaccines, therapeutics and preventive products that protect animals from disease and pain. In addition, the company achieved net sales of around 4.3 billion euros in the animal health sector in 2021, corresponding to 21 percent of the total net sales. The company's integrated product portfolio includes more than 200 products for dogs, cats, horses, pigs, cattle and poultry. The parasiticides NEXGARD and FRONTLINE for dogs and cats, HEARTGARD for dogs, and the pig vaccines INGELVAC CIRCOFLEX/ FLEXBOMBO are among the best-known brands. Furthermore, the company has an established global animal health innovation network with 18 R&D sites worldwide. The focus is innovative vaccines and parasiticides to protect livestock and companion animals and therapeutics for treating chronic diseases and other debilitating conditions.
Ingelvac PRRS MLV: Ingelvac PRRS MLV is a modified live PRRS vaccine that is safe in pigs, gilts, and sows at all stages of production in PRRS-positive herds. It offers cross-protection against heterologous challenges; (including the Lelystad virus) and has significantly reduced reproductive disorders and respiratory disease due to the PRRS virus.
• Trusted and field-proven
• Unique in its ability to be used in pigs (3 weeks or older), gilts, and sows at ANY stage of production
• Available in three convenient sizes (10, 50, and 250 doses)
The global animal biotechnology market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook